FDA clears Cipla’s generic Brovana
Brovana had a market value of approximately $438 million for the 12-month period ending April 2021, according to IQVIA.
The Food and Drug Administration has given Cipla the nod for arformoterol tartrate inhalation solution 15 mcg / 2 mL.
The medication is the generic of Sunovion Pharmaceuticals’ Brovana.
Brovana is indicated for long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
Brovana had a market value of approximately $438 million for the 12-month period ending April 2021, according to IQVIA.
The product is available for shipping immediately.